Daewoong Pharmaceutical Launches New Dosage of Dyslipidemia Treatment 'Crezet'... Expanding Prescription Scope

Daewoong Pharmaceutical's dyslipidemia treatment 'Crezet'
[Photo by Daewoong Pharmaceutical]

[Asia Economy Reporter Lee Gwanju] Daewoong Pharmaceutical announced on the 8th that it has launched a new dosage strength of its dyslipidemia treatment Crezet, 10/2.5 mg (Ezetimibe/Rosuvastatin). With this, Crezet now offers a total of four lineups, including the previously released 10/5 mg, 10/10 mg, and 10/20 mg.

The newly launched product features a reduced Rosuvastatin content of 2.5 mg compared to existing options. It is expected to establish itself as a new prescription option for patients in low to moderate risk groups and elderly patients who may find it difficult to start with a higher initial dose. The price is 750 KRW per tablet.

In a Phase 3 clinical trial of Crezet 10/2.5 mg conducted at 30 institutions including the Department of Cardiology at Bundang Seoul National University Hospital, the drug demonstrated superior LDL-C (low-density lipoprotein cholesterol) lowering effects by reducing LDL-C by 9.6% more compared to the control drug Rosuvastatin 5 mg. It also showed significant reductions in total cholesterol (TC), non-high-density lipoprotein cholesterol (Non-HDL-C), and apolipoprotein B (ApoB) by 6.6%, 8.3%, and 5.7%, respectively.

During the research and launch process, Daewoong Pharmaceutical reduced the pill size to enhance patient medication convenience and changed the packaging method from the conventional press-through packaging (PTP) to bottle packaging to improve dispensing convenience for medical staff.

Crezet, a combination of Rosuvastatin and Ezetimibe launched by Daewoong Pharmaceutical in 2016, is used to improve primary hypercholesterolemia and mixed dyslipidemia. It is effective in lowering LDL-C, improving lipid levels, and delaying the progression of coronary atherosclerosis. It can be taken once daily regardless of meals, enhancing medication adherence.

Lee Changjae, CEO of Daewoong Pharmaceutical, said, "Through this launch, we expect many patients to improve medication convenience and reduce treatment burdens with an economical price." He added, "As a leader in the cardiovascular and endocrine specialty pharmaceutical market, Daewoong Pharmaceutical will continue to do its best to provide various treatment options to medical professionals and patients based on excellent product quality and a differentiated four-step verification marketing strategy."

This content was produced with the assistance of AI translation services.